The purpose of this Cohort Treatment Plan is to allow access to nilotinib for eligible patients diagnosed with relapsed or refractory Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Currently, preliminary responses of nilotinib monotherapy in adults with refractory or relapsed Ph+ ALL show limited clinical benefit in this population of patients with a high unmet medical need. Remissions induced by imatinib are of short duration and resistance to imatinib represents a major clinical challenge. The exact benefit and role of nilotinib in this leukemia remains to be determined and requires further analysis. Until further data is available patients with Ph+ ALL should be treated with nilotinib through the Individual Patient Program.. Studies to date indicate that nilotinib may provide clinical benefit to Ph+ ALL patients and may represent a novel treatment option for these patients.
Drug: Nilotinib
The compassionate use dose of nilotinib is 400 mg orally twice daily and should not be taken with food
Inclusion Criteria:
The following criteria must be fulfilled for the provision of Managed Access and will vary
depending on the stage of the product lifecycle: - An independent request should be received from the Treating Physician (in some instances from Health Authorities, Institutions or Governments); - The patient to be treated has a serious or life threatening disease or condition, and no comparable or satisfactory alternative therapy is available to monitor or treat the disease or condition; - The patient is not eligible or able to enroll in a clinical trial; - There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated; - Provision of the investigational product will not interfere with the initiation, conduct or completion of a Novartis clinical trial or overall development program and - Such access provision as described above is allowed as per local laws and regulations.
Exclusion Criteria:
Patients eligible for inclusion in this Treatment Plan have to meet all of the following
criteria: 1. Male or Female patients age ≥ 18 years 2. WHO Performance Status of 0, 1 or 2 3. Relapsed or refractory Ph+ ALL 4. Imatinib (or dasatinib) must be discontinued at least 5 days prior to beginning therapy 5. Normal organ, electrolyte and marrow functions as described below: - Absolute Neutrophil Count (ANC) ≥ 1.0 x 1000000000/L - Platelets 50 x 1000000000/L - Potassium ≥ LLN (Lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of nilotinib - Total calcium (corrected for serum albumin) ≥ LLN - Magnesium ≥ LLN or corrected to within normal limits with supplements prior to the first dose of nilotinib medication - AST and ALT ≤ 2.5 x ULN or ≤ 5.0 x UL:N if considered due to tumor - Alkaline phosphatase ≤ 2.5 x ULN - Serum bilirubin ≤ 1.5 x ULN - Serum amylase and lipase ≤ 1.5 x ULN
Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com
Novartis Pharmaceuticals